About Us

M2 Biologics is a new player in the growing field of Regenerative Medicine. Formed in 2019 by The McGee Group, a leading eyewear design and manufacturing firm, and NovaNet, the largest preferred medical provider network in the Southeast U.S., M2 Biologics is committed to pioneering this exciting new field, generating patient referrals, and improving the lives of end-users.

NovaNet first ventured into the emerging field of Regenerative Medicine with the intention of distributing selected products that were being offered to both medical providers and hospitals. The team assembled included experts in clinical practice, scientific research, and sales/marketing. While there were some production laboratories and manufacturers that met NovaNet’s requirements, there were gaps in what the team felt needed to be available. With that, NovaNet set out on the mission to having its designed products manufactured for them.

The first products that NovaNet worked with were for the ophthalmologic/optometric market—the “Eye Doctors.” The founder of NovaNet approached the founder of The McGee Group and saw the obvious potential in a partnership. As the concept matured and the new organization coalesced, M2 Biologics, LLC was born.

Our Products

M2 Biologics, LLC is involved in the creation and distribution of biologics and bio-technology products. Working with our laboratory and development partner, Neobiosis, our efforts are in the Regenerative Medicine space.

With the mission of bringing breakthroughs in the burgeoning field of Regenerative medicine to the treatment of Dry Eye Disease, M2 Biologics is proud to introduce its first product—StimulEyes.

The basis of StimulEyes is human amniotic fluid. Both the collection and harvesting are done under the strictest controls. The mother has a comprehensive screening exam to ensure the absence of diseases. The collection is done only for scheduled caesarian section procedures.

Once procured, all of the processing is also done under strict state and federal guidelines.

The processed amniotic fluid contains no live stem cells. Rather, the compositional matrix is hyaluronic acid, bioactive proteins as anti-inflammatory cytokines and numerous growth factors.

This matrix has shown to have the effect of providing lubrication, reducing inflammation, and, we believe, working as a catalyst in the regeneration and repair of cells. When our matrix is combined with the progenitor cells already pervasive in the body, the observed outcomes have been quite impressive.

To top